#331
|
||||
|
||||
 äàííîì êîíòåêñòå ORR - Objective Response Rate?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#332
|
||||
|
||||
Âçàèìîñâÿçü ìåæäó ÊÐÀÑ ìóòàöèåé è îáüåêòèâíûì îòâåòîì íà ëå÷åíèå áûëà âûðàæåíà êàê îòíîñèòåëüíûé êîýôôèöèåíò îáüåêòèâíîãî îòâåòà íà ëå÷åíèå ó ïàöèåíòîâ ñ äàííîé ìóòàöèåé ê îáüåêòèâíîìó îòâåòó íà ëå÷åíèå ó ïàöèåíòîâ áåç ýòîé ìóòàöèè...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#333
|
||||
|
||||
 òàêîì ñëó÷àå 1 îáîçíà÷àåò îòñóòñòâèå ñâÿçè ìåæ ìóòàöèåé è ëå÷åíèåì, áîëåå 1 - áîëåå âûñîêàÿ ÷àñòîòà îòâåòà íà ëå÷åíèå cetuximab-îì ó ïàöèåíòîâ ñ äàííîé ìóòàöèåé è ìåíåå 1 - õóäøèé îòâåò íà ëå÷åíèå...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#334
|
|||
|
|||
|
#335
|
|||
|
|||
Funnel plot asymmetry was assessed by the method of Egger’s linear regression
test, a linear regression approach to measure funnel plot asymmetry on the natural logarithm scale of the RR. The significance of the intercept was determined by the t-test as suggested by Egger ( P < 0.05 was considered representative of statistically significant publication bias).  äàííîì ñëó÷àå - "ñìåùåíèå"? Ñïñ. |
#336
|
|||
|
|||
Åùå âîò ñ áóñò-îì....
Physicians had the option to choose between one of three fractionated radiation reg imens: once-daily, twice-daily or concomitant boost.
Êàê - "êðàñèâî" ñêàçàòü? |
#337
|
||||
|
||||
íàøåë â âèêè: This schedule, known as a concomitant boost regimen or hyperfractionation... èñïîëüçóþò ëè â ðóññêîì "ðåæèì ãèïåðôðàêöèîíèðîâàíèÿ"?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#338
|
|||
|
|||
Ãèïåðôðàêöèîíèðîâàíèå èñïîëüçóåòñÿ, íî ýòî íå òî.
Ãèïåðôðàêöèîíèðîâàíèå, ýòî ïî 5 Ãð õ 5 äíåé, à íå ïî 2,5 çà äåñÿòü. (ó íàñ îá÷÷íî ãîâîðèòñÿ "êðóïíûå ôðàêöèè") À boost - ýòî óâåëè÷åíèå äîçû äëÿ î÷àãà, ò.å. âåñü îðãàí/îáëàñòü ïîëó÷àåò, ê ïðèìåðó 45 ÃÐ, à íà ñàìó îïóõîëü äîâîäèòñÿ äî 62-70Ãð) |
#339
|
||||
|
||||
Concomitant boost radiotherapy (CBT) despite being a variant of accelerated fractionation, is associated with minimal enhancement of acute reactions because it uses the concepts of accelerated fractionation while minimizing the volume of tissue that is irradiated with high doses...
âñå ðàâíî ýòî âàðèàíò óñêîðåííîãî ôðàêöèîíèðîâàíèÿ, õîòÿ ðóññêèé ïåðåâîä ìíå íå ñîâñåì ïîíÿòåí... ìîæåò, çàäàéòå âîïðîñ äîêòîðó FRSM â ëè÷êó?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#340
|
|||
|
|||
In some cases, two fractions per day are used near the end of a course of treatment. This schedule, known as a concomitant boost regimen or hyperfractionation, is used on tumors that regenerate more quickly when they are smaller. In particular, tumors in the head-and-neck demonstrate this behavior.
Âîò ýòî ïîõîæå êàê ðàç ïî òåìå. Ò.å. ãèïåðôðàêöèîíèðîâàíèå ìîæíî ïðâåñòè â âèäå óêðóïíåíèÿ ôðàêöèé (5 âìåñòî 2,5) èëè ó÷àùåíèåì (ðàñùåïëåííîå ãèïåðôðàêöèîíèðîâàíèå) ïî 2,5 õ 2 ðàçà â äåíü. One of the best-known alternative fractionation schedules is Continuous Hyperfractionated Accelerated Radiation therapy (CHART). CHART, used to treat lung cancer, consists of three smaller fractions per day. Although reasonably successful, CHART can be a strain on radiation therapy departments. Another increasingly well-known alternative fractionation schedule, used to treat breast cancer, is called Accelerated Partial Breast Irradiation (APBI). APBI can be performed with either brachytherapy or with external beam radiation. APBI normally involves two high-dose fractions per day for five days, compared to whole breast irradiation, in which a single, smaller fraction is given five times a week over a six-to-seven-week period. |
#341
|
|||
|
|||
Äîáðîãî äíÿ/âå÷åðà!
Ãåíåòèêà âîò íàïðÿãàåò.... :-( a second gene, BRAF, the product of which is a downstream effector of KRAS in the MAPK pathway [12] |
#342
|
||||
|
||||
î÷åíü ïðèáëèçèòåëüíî...
"ïðîäóêò êîòîðîãî ÿâëÿåòñÿ ýôôåêòîðíûì áåëêîì KRAS, ó÷àñòâóþùèì â ïåðåäà÷e ñèãíàëà íèæå (äàëåå) ïî êàñêàäó MAPK"
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#343
|
|||
|
|||
Äûê îíè îáà ãåíû, è KRAS è BRAF....
Íàïðàøèâàåòñÿ, ÷òî ïðîäóêò BRAF "îêàçûâàåò óãíåòàþùèé/ñíèæàþùèé ýôôåêò" íà ôóíêöèþ KRAS â ñèãíàëüíîì êàñêàäå... Èëè ".. ÿâëÿåòñÿ ýôôåêòîðîì äëÿ KRAS, ïîñëåäóþùåãî â ñèãíàëüíîì êàñêàäå..." ? |
#344
|
||||
|
||||
è Ê-ðàñ è Á-ðàô - áåëêè (ïðîäóêòû ãåíîâ ñ àíàëîã. íàçâàíèÿìè), Ê-ðàñ ÷åðåç àêòèâàöèþ Á-ðàô àêòèâèçèðóåò ÌÀÏÊ êàñêàä, òàê ÷òî ïîñëåäîâàòåëüíîñòü àêòèâàöèè òàêàÿ: Ê-Ðàñ -> Á-ðàô -> ÌÀÏÊ...
...v-raf murine sarcoma viral oncogene homolog B1 (B-Raf), through which K-Ras activates the mitogen-activated protein kinase (MAPK) cascade... à çíà÷èò ïåðåâîä âñåé ôðàçû òî÷íåå òàê: "âòîðîé ãåí Á-ðàô, áåëîê (ïðîäóêò) êîòîðîãî ÿâëÿåòñÿ ýôôåêòîðíûì ïîñðåäíèêîì/êî-ôàêòîðîì Ê-ðàñ â àêòèâàöèè ÌÀÏÊ êàñêàäà"
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#345
|
|||
|
|||
Íó, ñ ìåíÿ íå îäíà ïëÿøêà..... ;-)
|